Alendronate medication possession ratio and the risk of second hip fracture:​ an 11-year population-based cohort study in Taiwan

Chen, Y. J.; Kung, P. T.; Chou, W. Y.; Tsai, W. C.

Affiliations

¹Department of Health Services Administration, China Medical University, Taiwan, Taichung, Republic of China

²Department of Orthopedic Surgery, China Medical University Hospital, Taiwan, Taichung, Republic of China

³School of Medicine, China Medical University, Taichung, Republic of China

⁴Department of Health Administration, Asia University, Taiwan, Taichung, Republic of China

⁵Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Republic of China

Abstract and keywords

Summary: Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the duration that is effective in preventing a second hip fracture. Our study demonstrated that risk can be reduced when the prescription is ≥ 6 months for the year following the index hip fracture.

Introduction: Alendronate is effective in preventing second hip fracture in osteoporotic patients. However, no consensus exists on the accurate medication possession ratio (MPR) that is effective in preventing a second hip fracture. Our objective was to compare the risk of second hip fracture in patients treated with different MPR of alendronate.

Methods: In this population-based cohort study, data from National Health Insurance Research Database of Taiwan were analyzed. Patients 50 years and older who had an index hip fracture and were not receiving any osteoporotic medications before their fracture during 2000–2010 were included. The cohort consisted of 88,320 patients who were new alendronate users (n = 9278) and non-users (n = 79,042). Those without alendronate were matched 4:1 as the control group. Patients were subdivided into those with no medication, MPR < 25%, MPR 25–50%, MPR 50–75%, and MPR 75–100%. Cox proportional hazard models were used to calculate the adjusted hazard ratios for different MPRs of alendronate.

Results: After matching, 38,675 patients were included in this study; 20,363 (52.7%) were women, and 30,940 (80%) patients were without medication of alendronate. During follow-up on December 31, 2012, 2392 patients had a second hip fracture, for an incidence of 1449/100,000 person-years. Patients with alendronate MPR 50–75% had a lower risk of a second hip fracture compared to non-users (hazard ratio 0.66). When the MPR increased to 75–100%, the hazard ratio decreased to 0.61.

Conclusions: In this population-based cohort study, risk of a second hip fracture can be reduced when the alendronate MPR is ≥ 50% for the year following the index hip fracture. As the MPR increases, the risk of a second hip fracture decreases.

Keywords: Alendronate; Bisphosphonate; Hip fracture; Medication possession ratio; Osteoporosis; Second hip fracture

Links

DOI: 10.1007/s00198-020-05399-9

PubMed: 32221674

WoS: 000521903500001

History

Received: 2019-10-16

Accepted: 2020-03-20

Online: 2020-03-27

Cited Works (2)

Year	Entry
2007	Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. NEJM. November 1, 2007;357(18):1799-1809.
2000	Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. April 2000;15(4):721-739.